Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash & Equivalents data on file, last reported at $288.3 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $288.3 million, down 45.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $288.3 million (down 45.39% YoY), and the FY2025 annual result was $294.9 million, up 4.6% from the prior year.
• Cash & Equivalents fell to $288.3 million in Q1 2026 per BEAM's latest filing, from $294.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $527.9 million in Q1 2025 and troughed at $156.5 million in Q3 2022.
• A 5-year average of $281.5 million and a median of $282.0 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 205.24% in 2022 and fell as far as 74.43% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $232.8 million in 2022, then soared by 87.27% to $435.9 million in 2023, then sank by 35.31% to $282.0 million in 2024, then advanced by 4.6% to $294.9 million in 2025, then declined by 2.26% to $288.3 million in 2026.
• Business Quant data shows BEAM's Cash & Equivalents at $288.3 million in Q1 2026, $294.9 million in Q4 2025, and $268.0 million in Q3 2025.